Rachel Layman, MD
M.D. Anderson Cancer Center · Ohio State University Comprehensive Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Rachel Layman, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:59 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT03101748 · Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast CancerM.D. Anderson Cancer Center · terminated · Breast Inflammatory Carcinoma, Locally Advanced Breast Carcinoma, Metastatic Breast Carcinoma · principal investigator
- Ph1/Ph2NCT00834678 · Bendamustine and Erlotinib in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Breast CancerOhio State University Comprehensive Cancer Center · completed · Breast Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:59 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in breast cancer.